Saturday, January 28, 2006


HCV - For schools, $274M notes


For schools, $274M notes
SouthCoastToday.com, MA - Jan 26, 2006... would increase public health spending by about $25 million, but still failed to provide needed increases in areas such as AIDS and hepatitis-C prevention and ...

U of Sask. researchers say the've found possible vaccine for ...
StarPhoenix, Canada - Jan 10, 2006SASKATOON -- Researchers at the University of Saskatchewan say they have found a possible vaccine to prevent hepatitis C. The researchers ...

U of S scientists develop promising hep C vaccine
CBC Saskatchewan, Canada - Jan 11, 2006There's no cure for hepatitis C, but scientists at the University of Saskatchewan think they've found a pretty good candidate for an effective vaccine. ...

Researchers Develop New Vaccine Candidate Against Hepatitis C
Science Daily (press release) - Jan 10, 2006... at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate for hepatitis C, leading to hope in ...

HIV/HCV coinfected patients have poorer immunologic response to ...
Aidsmap, UK - Jan 17, 2006HIV-positive patients who are coinfected with hepatitis C virus appear to have a less favourable immunological response to potent antiretroviral therapy than ...

HCV - Indenix is Nearing Phase III for Valopicitabine


Indenix is Nearing Phase III for Valopicitabine
It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are working on solutions to be used with interferon are not really offering anything groundbreaking or revolutionary, it does continue the...

Pill Form of Therapy for HCV Coming Closer
This report is an update of therapy progress presented at the AASLD (American Academy for the Study of Liver Diseases). Three separate approaches are covered. Yes, progress is being made....

Vertex Progresses with VX-950
Vertex is the racehorse to watch right now. They are progressing quicky on their preliminary good results. While it's not yet time to line up for their treatment, we believe theirs will be first to market of the new approaches...

Conclusions About Milk Thistle
A May 2005 review of clinical studies which casts doubt on milk thistle's value has recently been re-released into the press. Alternatively, an extensive amount of research supports the continued usage of this herb at higher dosages. Researchers of the...

Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a shorter course of treatment might be just as effective as longer courses. Researchers continue to refine treatment protocols for HCV...

Friday, January 27, 2006


HCV - Hep C life after


Hep C life after
Hep C life after interferon LIFE AFTER MY 48 WEEK OF PEG/RIBA ROLLARCOASTER 21/03/03 till 15/02/04 "In my previous lives, I was: A woman with

Hepatitis C Symptoms - Hepatitis C Treatments - Hepatitis C
LINKS TO INFORMATION FOR HEP C TREATMENT: http://nccam.nih.gov/health/hepatitisc/ - This link discusses the conventional and alternative methods (CAM Complimentary and

Methadone Anonymous -- View Forum - HIV / HCV in the News
Marijuana just how bad is it for us with Hep C??? truetildeath13 4 531 Sun Jan 15, 2006 3:39 pm korshoski HIV Tracking System May Be Scrapped Bev 0 264 Tue Jul 26, 2005 10:04 am Bev AIDS Crisis Brings Radical

Hep C Boy Blog Archive My Hepatitis C
I told my foreman on Jan. 13 2003 about my hep C. I got a letter in my file the next day.I see there point in a way. They wouldn t want a person with Hep C running the water treatment plant. This

HEP C MATCH: hepatitis c information, hep c chat, liver specialists
At Hep C Match you will find Hepatitis C Support from other members and potential dates (or mates) you will meet through this Hep C Dating website. HEP C INFO, LINKS AND MORE HEP C DOCTORS I

SacMall.Net - Transplant News Advisor - Hep C
Home | Kidney | Liver | Lung | Hep C | Misc | Other Support

HCV - Savage Love: The Ultimate Cuckold Fetish


Savage Love: The Ultimate Cuckold Fetish
Village Voice - Q. My girlfriend of three years is a smoker. For a while her smoking didn't bother me. I come from a family of smokers, and I used to smoke. But now it's a huge turnoff. I've started a new job where I work with cancer patients and see the deadly

Updates from JP Morgan's 24th Annual Healthcare Conference
Boston Globe - Anyone who still believes that a halo of glamour surrounds the life of a globetrotting money manager needed to be in the lobby of the St. Francis Hotel in San Francisco this morning, where at 7:45 with picturesque cable cars climbing through a

Files on infected blood destroyed
BBC UK - The UK Government has admitted that nearly all its files on the infection of patients through NHS blood products have been destroyed. Hundreds of haemophiliacs and other patients were infected with hepatitis C or HIV in the 1980s and early 1990s. The

Island addicts need free needles: AIDS PEI
CBC News - Addicts on Prince Edward Island are desperate for a free needle exchange, according to Barb Gibson, executive director of AIDS PEI. P.E.I. is the only province in Canada without a provincially-funded needle exchange. The only way for addicts to get

Weis keeps his word in the recruiting process
Sporting News - The recruiting game has become more and more about who you can trust and who you can't. Can you trust 17-year-old kids who give you a verbal commitment six months before Signing Day? Will you stop recruiting a certain position because a hotshot stud

Thursday, January 26, 2006


HCV - Hepatitis C Virus Lives In Your Liver(NC)-Your liver

Hepatitis C Virus Lives In Your Liver

(NC)-Your liver works 24 hours a day, performing over 500 vital functions for your body. Most of the blood that returns to your heart passes through the liver. Your body can't function without it.

The hepatitis C virus lives in your liver. It inflames liver cells, which, over time, affects the way your liver functions. The effect of the hepatitis C virus varies from person to person. There is no way to predict how your body will react to it. There are, however, some things that are known:

You can live with hepatitis C for many years without experiencing any major symptoms, or you might simply feel tired. Symptoms can come and go over time. Their presence or absence does not tell you the degree to which liver damage may or may not be occurring. p>

Chronic, long-term inflammation of the liver can cause liver cell damage and result in fibrosis (liver scarring), or even cirrhosis. This damage can occur in as little as five years, or as long as 30 years.

About 20% of chronic hepatitis patients develop cirrhosis within 10 to 20 years.

Use of recreational drugs or alcohol can speed up inflammation and the development of fibrosis or cirrhosis.

There is an increased risk of liver cancer in people with cirrhosis.

The good news is that current drug treatments can be very effective for people with hepatitis C. Combined with proper nutrition, plenty of rest, and avoidance of recreational drugs and alcohol, these treatments help many who have the virus lead relatively healthy lives.

If you think you may be at risk of getting hepatitis C, see your doctor. The virus can be detected by a simple blood test. For more information on how to keep your liver happy and healthy, visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

p>

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services. p>


Wednesday, January 25, 2006


HCV - InterMune Completes Divestiture of Infergen(R) for up to $135.5 ...


InterMune Completes Divestiture of Infergen(R) for up to $135.5 ...
PR Newswire (press release), NY - Jan 3, 2006... of its United States and Canadian rights to Infergen(R) (interferon alfacon-1), approved for the treatment of chronic hepatitis C virus (HCV) infections, to ...

Habitat Building to a Big Year
Bremerton Sun (subscription), United States - Jan 4, 2006... One piece deals with funding for HCV (hepatitis C virus) education aimed at the general population. Another is regulation of tattooing and body piercing. ...

HAART reduces liver-related death risk, but hepatitis C infection ...
Aidsmap, UK - Jan 18, 2006... antiretroviral therapy (HAART) reduces the risk of liver-related death by 68%, although infection with both HIV and hepatitis C virus (HCV) increases the risk ...

Grayling Housing Commission 1 of 3 to receive extra federal ...
Gaylord Herald Times, MI - Dec 28, 2005... The Housing Choice Voucher-Family Self-Sufficiency (HCV-FSS) Grant received by the Grayling Housing Commission provides funds to pay the salary of a program ...

Human Genome Sciences Reports on Progress Toward Commercialization ...
PR Newswire (press release), NY - Jan 10, 2006... Albuferon(TM) (albumin-interferon alpha 2b), a novel long-acting form of interferon alpha for the treatment of chronic hepatitis C (HCV) In April 2005, the ...

Tuesday, January 24, 2006


HCV - A Summary of Chronic Hepatitis C InfectionHepatitis C

A Summary of Chronic Hepatitis C Infection

Hepatitis C is a stealthy virus that mutates while hiding in liver cells and other organ cells like the spleen and gall bladder. The fact that the viral cells "hide" makes it very difficult for the body's immune system to eradicate it. Hepatitis C is a slowly progressing disease sometimes taking many years until symptoms are noticeable. It is at this point that the virus has reached advanced chronic stage and becomes difficult to eradicate. Hepatitis C results in 8,000 to 10,000 deaths annually. Hepatitis C is also the leading cause of liver transplants in the U.S.

Hepatitis C infection is caused by blood contact with someone who has the virus infection himself. The transmission of the virus can occur by illicit drug use with needles, sharing toothbrushes or razors with an infected person, by sexual means, by unsanitary tattooing or by exposure to blood at your workplace (like a hospital or blood bank). Some HCV infection may have been caused by receiving blood from a transfusion prior to 1992.

Hepatitis C is diagnosed via a blood test. Usually, the first thing that is noticed is that the liver enzyme levels for ALT and AST are elevated well above normal levels. Further investigation via HCV-RNA testing identifies whether the Hepatitis C virus is in your blood or not. Other tests for HCV include qualitative viral load tests, which measure the RNA particles in your blood. If you are being treated for HCV, your doctor is probably using either a HCV-RNA or viral load test to determine the effectiveness of the treatment.

The symptoms of Hepatitis C infection often do not occur in a person until 20 years after he/she had been infected. Since the HCV infects the liver and the liver is the organ in the body that makes all the energy for our daily activities possible, liver function deterioration often results in fatigue. Fatigue is the primary complaint or symptom of HCV infection. Other more severe symptoms are jaundice (yellowing of the skin/eyes), bile retention (which can cause jaundice), portal vein hypertension, skin rashes and itching, and autoimmune problems resulting from your body's immune system attacking normal cells.

Long term HCV infection may result in fibrosis or even cirrhosis of the liver. Fibrosis results from unchecked liver inflammation. As the HCV infection progresses, the damage to the liver results in scarring or hardening of the liver cells (fibrosis). Long term fibrosis may lead to cirrhosis which is when the scarring from fibrosis overtakes the normal liver cell structure causing deformity and loss of function in the liver. About 15%-20% of HCV patients end up with cirrhosis. A liver biopsy is currently the most accurate means of determining the amount of inflammation and fibrosis the liver has sustained.

Hepatitis C progression in the body can take several years or even decades to come to chronic stage or to a stage where severe liver damage is evident. This period of time allows a person to determine how to properly treat the disease and to decide on a course of disease management. Currently, the main treatment for HCV infection to eradicate the virus is combo alpha-interferon and Ribavirin. Sometimes a doctor may prescribe interferon alone. Interferon comes in standard form or in pegylated form. Standard form interferon is administered 3 times per week, while the pegylated form is administered only once per week. Your body makes its own interferon, which is a protein that fights viral infection and viral replication.

Hepatitis C may often be managed by taking herbal and vitamin supplements that help your body fight infection and limit inflammation. These supplements help your liver with the inflammation and give it the nutrients it needs to regenerate healthy new cells. Your doctor can recommend alternative or adjunct solutions you may want to try.

Proper treatment of the disease, a healthy and active lifestyle, a good diet, abstinence from alcohol and stress management are important factors in controlling Hepatitis C progression.

About the Author

Greg Lietz is a freelance writer and internet businessman. His main website is http://www.theonlinebizplace.com where he provides content about internet based business opportunities and different niche interests. This article may be freely printed when the bio information is included.

Monday, January 23, 2006


HCV - Difficulty In Treating Older Hepatitis C Patients With Combination Therapy


Difficulty In Treating Older Hepatitis C Patients With Combination Therapy
Medical News Today - Jan 07 8:07 AM
A new study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group.Save to My Web

AVI BioPharma's NEUGENE Shows Success Against Deadly Ebola Virus
[Press Release] Business Wire via Yahoo! Finance - Jan 13 6:00 AM
PORTLAND, Ore.----Jan. 13, 2006--AVI BioPharma, Inc. , today announced publication of significant research carried out in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases .Save to My Web

MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment Naive Patients; CEO Message No. 17 Released
[Press Release] CNW Group via Yahoo! Finance - Jan 23 9:19 AM
MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, released the Company's 17th CEO Message today. The CEO Message provides an overview of the MX-3253 and CPI-226 clinical programs for 2006 and the first half of 2007, including the Company's plan to initiate a combination therapy viral kinetics clinical trial of celgosivir in Hepatitis C virus patients.Save to My Web

Peregrine accelerates Tarvacin development
Pharmaceutical Business Review - Jan 19 6:08 PM
Californian biopharm company Peregrine Pharmaceuticals has accelerated its clinical program for Tarvacin, an anti-viral designed to treat chronic hepatitis C, expecting to complete patient dosing in its present study months ahead of schedule.Save to My Web

HGS Signs Amgen, PDL For Partners In Non-Core Assets
BioWorld - Jan 10 6:05 PM
In a flurry of activity this week, Human Genome Sciences Inc. and its recently formed CoGenesys division agreed to a pair of out-licensing deals, and at the same time, the parent firm received a $5 million milestone payment as part of an older agreement.Save to My Web

HCV - Chapter 14 - Section 4: First Principles of Gastroenterology


Chapter 14 - Section 4: First Principles of Gastroenterology
... C are the commonest causes of viral hepatitis. Viral hepatitis occurs less commonly with infections such ... decade, the treatment of acute viral hepatitis has not progressed as rapidly ...

Hepatitis C - Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted - information page with HONselect
<A HREF='/cgi-bin/HONselect?browse+C23.550.470' OnMouseOver= ... HONcode - Hepatitis C: FAQ | CDC Viral Hepatitis. www.cdc.gov ...

Viral Hepatitis Surveillance and Prevention Update (PDF)
Viral Hepatitis Surveillance. Acute cases of hepatitis A, B, C, delta, and non-A/ non-B are physician reportable, and clinical tests. indicative of viral hepatitis infection are laboratory. reportable. Surveillance case definitions for acute ... acute cases of viral hepatitis to the Connecticut. Department of Public ...

FDHN: The ABC's of Viral Hepatitis A, B, & C
The ABC's of Viral Hepatitis A, B & C. What is viral hepatitis? Viral hepatitis is a disease caused by viruses that damage your liver. This damage can make your liver inflamed, swollen and tender. ... The most common forms of viral hepatitis include hepatitis A, hepatitis B and ...

Viral Hepatitis (PDF)
Pathology of viral disease. Ila R. Singh, M.D., Ph.D. 10/8/2004. Clinical Pathology/Lab Medicine 2002. 1. The ABCs of. Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S 14-453. is132@columbia.edu. Viral Hepatitis. Hepatotropic viruses

Sunday, January 22, 2006


HCV - HGS Signs Amgen, PDL For Partners In Non-Core Assets


HGS Signs Amgen, PDL For Partners In Non-Core Assets
BioWorld Online (subscription), GA - Jan 10, 2006... Also, the company expects to start Phase III development of Albuferon (albumin-interferon alpha 2b) for chronic hepatitis C by the end of 2006, assuming ...

Hepatitis C Patients Taxing Medical System
Forbes - Dec 30, 2005About 3 million people in the United States have chronic hepatitis C virus (HCV), and many of them contracted it in the 1970s, before testing and safe needle ...

Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ...
PR Newswire (press release), NY - Jan 4, 2006... recombinant interferon-alpha 2-b), for the treatment of malignant melanoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, chronic hepatitis C and chronic ...

Organ Donor Rates for 2005 Worst Ever.
Scoop.co.nz (press release), New Zealand - Jan 10, 2006... expected to double over the next decade, requiring more donors due the expected doubling of end stage liver disease from chronic hepatitis C. (Currently there ...

Peregrine accelerates Tarvacin development
Pharmaceutical Business Review - Jan 19, 2006... biopharm company Peregrine Pharmaceuticals has accelerated its clinical program for Tarvacin, an anti-viral designed to treat chronic hepatitis C, expecting to ...